Syndecans and Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC) is a fatal disease with poor prognosis because patients rarely express symptoms in initial stages, which prevents early detection and diagnosis. Syndecans, a subfamily of proteoglycans, are involved in many physiological processes including cell proliferation,...
Main Authors: | Nausika Betriu, Juan Bertran-Mas, Anna Andreeva, Carlos E. Semino |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/3/349 |
Similar Items
-
Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells
by: Nausika Betriu, et al.
Published: (2021-09-01) -
Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression
by: Zongfu Pan, et al.
Published: (2018-12-01) -
Syndecans as modulators and potential pharmacological targets in cancer progression
by: Despoina eBarbouri, et al.
Published: (2014-02-01) -
The Cardiac Syndecan-2 Interactome
by: Sabrina Bech Mathiesen, et al.
Published: (2020-08-01) -
MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression
by: Run-Fen Cheng, et al.
Published: (2016-07-01)